Infliximab is a chimeric anti-tumour necrosis factor-alpha monoclonal antibody that has been
studied for the treatment of Crohn's disease and rheumatoid arthritis. In several placebo …

Infliximab, a chimeric monoclonal antibody to tumour necrosis factor‐alpha, contains murine
protein elements and targets the immune system, raising concerns about the potential for …

Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor
(TNF)-α that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease …

Infliximab | BioDrugs Skip to main content SpringerLink Account Menu Find a journal Publish
with us Track your research Search Cart 1.Home 2.BioDrugs 3.Article Infliximab An Updated …

Infliximab is a chimaeric monoclonal antibody which binds to and inhibits the activity of
tumour necrosis factor-α (TNFα), a cytokine which is involved in the development of both …

Background & Aims: The aim of this study was to evaluate the short-and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records …

OBJECTIVE: To determine whether the clinical efficacy and safety of infliximab in diverse
clinical referral practices was similar to that seen in the randomized, controlled clinical trials …

Infliximab (Remicade™, Centocor, Inc.) is an intravenously administered monoclonal
antibody to TNF proven effective in the treatment of moderate-to-severe Crohn's disease …

Infliximab is a monoclonal antibody directed against the pro-inflammatory mediator TNF-α,
which was approved in the US in 1998 for treatment-resistant Crohn's disease. Since that …

Background The aim of this study was to evaluate the short-and long-term safety experience
of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. Methods The …